18 citations
,
June 2017 in “Journal of the neurological sciences” In this study, the use of 5 alpha reductase inhibitors was associated with an increased risk of dementia during the first two years of treatment, but the risk was not significant with longer exposure.
90 citations
,
March 2017 in “JAMA Internal Medicine” In this study, older men using 5α-reductase inhibitors for prostatic enlargement did not show increased risk of suicide, but had elevated risks of self-harm and depression.
10 citations
,
January 2017 in “Skin Pharmacology and Physiology” This case report describes a 52-year-old man who developed generalized vitiligo two months after stopping finasteride and suggests this may be part of post-finasteride syndrome.
50 citations
,
September 2016 in “The Journal of Clinical Endocrinology and Metabolism” This study found no evidence of androgen deficiency or decreased peripheral androgen action in men with persistent sexual symptoms after finasteride use, but identified links to depressed mood and abnormal brain function.
30 citations
,
September 2016 in “BMJ” This study found that 5-α reductase inhibitors do not significantly increase the risk of erectile dysfunction in men with benign prostatic hyperplasia or alopecia, although duration of benign prostatic hyperplasia may elevate risk.
57 citations
,
July 2016 in “The Journal of Sexual Medicine” This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.
15 citations
,
July 2016 in “Urologic Clinics of North America” This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.
3 citations
,
October 2015 in “Human Psychopharmacology-clinical and Experimental” In this study, finasteride was found not to be associated with changes in sleep spindle activity or morphology in men undergoing sleep studies.
49 citations
,
September 2015 in “Psychoneuroendocrinology” This study suggests that the 5α-reductase inhibitor finasteride modulates sensorimotor gating in rats by affecting D1 and D3 receptors, but not D2 receptors, with varying effects based on genetic strain.
6 citations
,
March 2015 in “Journal of Endocrinological Investigation” This study suggests that using both finasteride and dutasteride may increase the risk of acute coronary syndrome in patients with benign prostate hyperplasia.
56 citations
,
January 2015 in “Circulation” This study found that finasteride treatment improved cardiac function and reduced heart failure progression in mice, suggesting it could be a potential therapy for pathological cardiac hypertrophy and dysfunction.
28 citations
,
August 2014 in “Cancer Causes & Control” In this study, there was no evidence that using 5α-reductase inhibitors for either short or long durations increased the risk of male breast cancer.
81 citations
,
June 2014 in “American Journal of Men's Health” This study highlights that adverse effects from finasteride may persist in men after discontinuation, indicating a potential "post-finasteride syndrome.
32 citations
,
May 2013 in “The Journal of Urology” This study found no statistically significant association between the use of 5α-reductase inhibitors and male breast cancer incidence.
42 citations
,
August 2012 in “Psychoneuroendocrinology” Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.
185 citations
,
March 2011 in “The Journal of Sexual Medicine” This study found that 94% of healthy men reported low libido and 92% reported erectile dysfunction as persistent sexual side effects after using finasteride for male pattern hair loss, with these effects lasting on average 40 months post-discontinuation.
1707 citations
,
December 2003 in “The New England Journal of Medicine” Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.